You have 2 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase Ib, BRAF-mutated, BRAF V600E, BRAF V600D, BRAF V600K, colorectal cancer, colon cancer, rectal cancer, metastatic, BLRM with EWOC

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

Active, not recruiting
  • BRAF V600E Mutation Present
  • +9 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2022

Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

Recruiting
  • Anaplastic Thyroid Cancer
  • ATC
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

Melanoma Trial in Beijing (HL-085, Vemurafenib)

Recruiting
  • Melanoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 10, 2022

Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

Recruiting
  • Metastatic Melanoma
  • BRAF Gene Mutation
  • Nilotinib 100mg
  • +5 more
  • Lexington, Kentucky
    Markey Cancer Center
Jul 22, 2022

Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

Not yet recruiting
  • Advanced Solid Tumor
  • BRAF V600 Mutation
  • Nanchang, Jiangxi, China
  • +2 more
Aug 12, 2022

Colorectal Cancer Trial in Shanghai (Vemurafenib, Cetuximab)

Recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 15, 2021

Primary Malignant Brain Tumor Trial in China (ABM-1310)

Not yet recruiting
  • Primary Malignant Brain Tumor
  • Beijing, Beijing, China
  • +3 more
May 28, 2023

Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
  • +2 more
Jun 14, 2022

Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

Terminated
Has Results
  • Malignant Melanoma
  • Brain Metastases
  • Tucson, Arizona
    University of Arizona Cancer Center
Mar 5, 2022

BRAF V600E, Metastatic Colorectal Cancer Trial in China (Encorafenib, Cetuximab, FOLFIRI)

Recruiting
  • BRAF V600E
  • Metastatic Colorectal Cancer
  • Beijing, Beijing, China
  • +33 more
Dec 20, 2022

Advanced Solid Tumor, BRAF V600 Mutation Trial in United States (ABM-1310, Cobimetinib)

Recruiting
  • Advanced Solid Tumor
  • BRAF V600 Mutation
  • San Francisco, California
  • +3 more
Dec 30, 2022

Brain Tumor, Primary Trial in Jinan (HLX208)

Recruiting
  • Brain Tumor, Primary
  • Jinan, Shandong, China
    Cancer Hospital Affiliated to Shandong first medical University
May 1, 2022

Solid Tumor Trial in Guangzhou (HLX 208)

Recruiting
  • Solid Tumor
  • HLX 208
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Jan 26, 2022

NSCLC Trial in China (Dabrafenib, Trametinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Harbin, Heilongjiang, China
  • +9 more
Jun 13, 2022

Liquid Biopsy, Melanoma (Skin), Melanoma Stage III Trial in Rome (Affinity Mediated Transport Amplification (AMT))

Recruiting
  • Liquid Biopsy
  • +4 more
  • Affinity Mediated Transport Amplification (AMT)
  • Rome, Italy
    "Regina Elena" National Cancer Institute
Jul 13, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +4 more
  • Dabrafenib Mesylate
  • +3 more
  • Philadelphia, Pennsylvania
    Perelman Center for Advanced Medicine
Dec 29, 2021

Advanced Melanoma Trial in China (HLX208)

Recruiting
  • Advanced Melanoma
  • Peking, Beijing, China
  • +6 more
May 1, 2022

NSCLC Trial in Shanghai (HLX208)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai chest hospital
Jan 5, 2022

First Line Treatment for BRAFV600E Mutant Metastatic Colorectal

Completed
  • BRAF V600E Mutation Positive
  • Metastatic Colorectal Cancer
  • Non Interventional study
  • St. Veit/Glan, Austria
  • +33 more
Jan 20, 2023

Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas Trial in Canada, United States (Vemurafenib)

Active, not recruiting
  • Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
  • Los Angeles, California
  • +20 more
Jan 4, 2023

NSCLC Trial in China, Taiwan (Encorafenib, Binimetinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Beijing, China
  • +35 more
Jun 29, 2022

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Solid Tumors, Melanoma, NSCLC Trial in France, Spain, United States (CFT1946, Trametinib)

Recruiting
  • Solid Tumors
  • +4 more
  • Boston, Massachusetts
  • +9 more
Dec 19, 2022

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023